Does UnitedHealthcare Cover Mounjaro?

How UnitedHealthcare Classifies Mounjaro on Its Formulary

UnitedHealthcare places Mounjaro (tirzepatide) on Tier 3 of its standard commercial formulary, categorizing it as a preferred brand-name medication. Tier 3 copays on UHC plans typically range from $50 to $100 per fill, though the exact amount depends on your specific plan design. Members with high-deductible health plans (HDHPs) may pay the full $1,023 list price until the deductible is met.

What Tier 3 Means for Your Copay

Tier 3 sits above generic medications (Tier 1) and preferred generics (Tier 2) but below specialty or non-preferred drugs on Tier 4 or higher. The practical result: you pay more than you would for metformin, but less than you would for a non-formulary biologic. UHC updates its formulary quarterly, and tirzepatide's tier status has remained stable since the drug's FDA approval in May 2022 for type 2 diabetes.

Employer-Sponsored vs. Marketplace Plans

Not every UHC plan uses the same formulary. Self-funded employer plans can exclude GLP-1 receptor agonists entirely or move them to a higher tier. If you have a UHC Marketplace (ACA) plan, check your plan's Summary of Benefits and Coverage (SBC) document. The formulary search tool at UHC's member portal will confirm your specific tier and any restrictions.

Prior Authorization Requirements for Mounjaro

UnitedHealthcare requires prior authorization (PA) before dispensing Mounjaro. Your prescribing clinician submits clinical documentation to UHC's pharmacy benefit manager (OptumRx for most commercial plans), and a decision typically arrives within 5 to 10 business days. Urgent requests can be processed in 24 to 72 hours.

What the PA Form Asks For

The PA criteria for tirzepatide on UHC commercial plans generally require:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• A recent HbA1c value of 7.0% or higher
• Documentation of trial and failure (or contraindication) of metformin
• Prescriber attestation that the patient is not using tirzepatide solely for weight management

Some plans add a requirement for a second-line agent failure, such as a sulfonylurea or SGLT2 inhibitor, before approving tirzepatide. This is the step therapy component discussed below.

How to Speed Up Approval

Clinicians can reduce PA turnaround by submitting the most recent HbA1c lab result (drawn within 90 days), a medication history showing prior agents tried, and a brief clinical rationale explaining why tirzepatide is appropriate. Electronic PA (ePA) submissions through the OptumRx portal process faster than faxed forms.

Step Therapy: What UHC Expects You to Try First

Many UnitedHealthcare plans enforce step therapy for Mounjaro. Step therapy means the plan requires evidence that a patient tried and failed (or cannot tolerate) one or more lower-cost medications before it will approve a higher-cost drug. For tirzepatide, the most common step therapy sequence is metformin first, then a second agent such as a sulfonylurea or an SGLT2 inhibitor.

The Clinical Logic Behind Step Therapy

The American Diabetes Association (ADA) Standards of Care recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes. UHC's step therapy policy mirrors this guideline. The ADA also supports early use of GLP-1 receptor agonists in patients with established cardiovascular disease or high cardiovascular risk, a detail that can help bypass step therapy requirements if documented properly.

Exceptions to Step Therapy

Your clinician can request a step therapy override if you have a documented allergy or adverse reaction to metformin, a contraindication such as an eGFR below 30 mL/min/1.73m², or if you meet ADA criteria for early injectable therapy (HbA1c above 10% or symptomatic hyperglycemia). The override request is submitted as part of the PA process.

Does UnitedHealthcare Cover Mounjaro for Weight Loss?

UHC does not routinely cover Mounjaro for weight loss or obesity management under its standard commercial formulary. Tirzepatide received FDA approval for chronic weight management under the brand name Zepbound in November 2023, but Zepbound carries a separate National Drug Code (NDC), and many UHC plans either exclude anti-obesity medications entirely or place them on a non-covered tier.

The T2D vs. Obesity Distinction

If a member has both type 2 diabetes and obesity, the PA is submitted under the diabetes indication, and coverage follows the standard Tier 3 pathway. The distinction matters: a prescription written for "weight management" alone will likely trigger a denial, while the same molecule prescribed for "type 2 diabetes with concurrent obesity" follows the covered pathway. Your clinician should code the primary diagnosis as type 2 diabetes (E11.x) rather than obesity (E66.x) when both conditions are present.

Employer Carve-Outs for Obesity

A growing number of large employers have added anti-obesity medication (AOM) riders to their UHC plans. These riders may cover Zepbound or Mounjaro for obesity at varying cost-sharing levels. The only way to confirm whether your employer's plan includes this benefit is to call the number on the back of your UHC card or check your plan's drug list.

Clinical Evidence Supporting Mounjaro Coverage

Tirzepatide is a dual GIP/GLP-1 receptor agonist that demonstrated strong glycemic and weight-loss outcomes in the SURPASS clinical trial program. Payers like UHC base formulary decisions partly on this evidence.

SURPASS-2 Results

In the SURPASS-2 trial (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.58% from baseline at 40 weeks, compared with 1.86% for semaglutide 1 mg. Mean weight loss reached 12.4 kg (27.3 lb) with tirzepatide 15 mg versus 6.2 kg (13.7 lb) with semaglutide 1 mg. These head-to-head data position tirzepatide as the most potent injectable glucose-lowering agent currently available.

SURPASS-4 Cardiovascular Safety

The SURPASS-4 trial (N=2,002) enrolled patients with type 2 diabetes and high cardiovascular risk and followed them for up to two years. Tirzepatide showed non-inferior cardiovascular safety compared with insulin glargine, with a hazard ratio for major adverse cardiovascular events (MACE) of 0.74 (95% CI: 0.51 to 1.08). While not powered for cardiovascular superiority, the point estimate favored tirzepatide. The dedicated cardiovascular outcomes trial, SURPASS-CVOT, is ongoing with results expected by 2027.

How Trial Data Helps Your PA

Referencing SURPASS-2 data in a PA appeal can strengthen the case for tirzepatide over older GLP-1 agonists, especially when a patient has not reached goal HbA1c on semaglutide or dulaglutide. The head-to-head superiority data give clinicians a concrete clinical rationale that peer reviewers at OptumRx recognize.

What Mounjaro Costs with UnitedHealthcare

The sticker price for Mounjaro is $1,023 per month (four weekly injections per carton) at Eli Lilly's published list price. What you actually pay depends on your plan tier, deductible status, and whether you use a savings card.

Typical Out-of-Pocket Scenarios

| Scenario | Estimated Monthly Cost | |---|---| | Tier 3 copay (standard PPO) | $50 to $100 | | Tier 3 coinsurance (25%) after deductible | ~$256 | | HDHP before deductible met | $1,023 | | With Lilly savings card (eligible commercial) | As low as $25 | | No insurance / cash pay | $1,023 |

The Eli Lilly Savings Card

Eli Lilly offers a manufacturer savings card that can reduce copays to as low as $25 per month for commercially insured patients. The card covers up to $150 per fill in copay assistance and is not valid for government-funded insurance (Medicare, Medicaid, Tricare). Members with UHC commercial plans can stack the savings card on top of their insurance benefit, reducing out-of-pocket costs significantly while the deductible accumulates.

How to Appeal a UnitedHealthcare Denial of Mounjaro

If UHC denies your prior authorization for Mounjaro, you have a structured appeal pathway. The process has three stages, and data from the ADA Standards of Care can support each level.

Level 1: First Internal Appeal

You or your clinician submit a written appeal within 180 days of the denial. Include the denial letter, updated lab work (HbA1c, fasting glucose), a medication history documenting prior agent failures, and a letter of medical necessity. Reference specific trial data. For example: "In SURPASS-2 (N=1,879), tirzepatide 15 mg achieved 2.58% HbA1c reduction at 40 weeks, exceeding semaglutide 1 mg by 0.72 percentage points [1]. This patient has not reached glycemic targets on semaglutide 1 mg after 6 months." UHC must respond within 30 calendar days for standard appeals or 72 hours for expedited (urgent) appeals.

Level 2: Second Internal Appeal

If the Level 1 appeal is denied, you can file a second internal appeal with additional clinical documentation. This is your opportunity to include peer-reviewed literature, specialist consultation notes, or documentation of adverse events on alternative therapies. Some members include a letter from an endocrinologist supporting the medical necessity of tirzepatide specifically.

Level 3: External Independent Review

After exhausting both internal appeals, you can request an external review by an Independent Review Organization (IRO). The IRO is a third-party entity not affiliated with UHC. Under federal law (the ACA), the IRO's decision is binding on the insurer. External reviews are free to the member. The IRO typically issues a decision within 45 days, or 72 hours for expedited cases.

Tips for a Successful Appeal

Keep records of every submission date and reference number. Submit appeals by certified mail or through the UHC member portal with delivery confirmation. Ask your clinician to use peer-to-peer review (a direct phone call between your doctor and the UHC medical director) before escalating to Level 2. Peer-to-peer reviews resolve a meaningful percentage of PA denials without requiring a formal written appeal.

Switching Plans or Timing Your Enrollment

Open enrollment decisions affect Mounjaro access. If your current UHC plan excludes GLP-1 agonists or places them on a non-preferred tier, you may find better coverage by selecting a different plan option during your employer's annual enrollment period (typically October or November for a January 1 effective date).

What to Check Before Switching

Review the formulary for each plan option your employer offers. Confirm the tier for tirzepatide, whether PA is required, and whether step therapy applies. Compare the total annual cost: a plan with a higher premium but lower specialty copay may cost less overall if you fill Mounjaro monthly. Use UHC's formulary lookup tool or call OptumRx directly at the number on the back of your insurance card.

Medicare and Medicaid Considerations

Medicare Part D plans have historically excluded anti-obesity medications, but under the Treat and Reduce Obesity Act provisions taking effect in 2026, some Part D plans are beginning to cover GLP-1 agonists for obesity. For type 2 diabetes, Medicare Part D does cover Mounjaro, though formulary tier and PA requirements vary by plan. Medicaid coverage varies by state. Check your state's preferred drug list (PDL) for tirzepatide's status.